Poolbeg Pharma

Activities: Drug Delivery

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Research & Development

Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Regulatory

Poolbeg Pharma granted European patent for flu drug

POLB 001 targets the body's inflammation machinery and prevents dangerous immune overreactions. The drug could also be used in the treatment of other inflammation-based diseases, such as Cytokine Release Syndrome
Regulatory

Poolbeg granted FDA Orphan Drug Designation for POLB 001

The US FDA grants orphan status to support the development of medicines for rare disorders affecting fewer than 200,000 people in the US
Finance

HOOKIPA Pharma begins non-binding discussions to acquire Poolbeg Pharma

The two pharmaceutical companies may create a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation immunotherapies
Finance

Cytokine release syndrome preventative therapy could be a >$10bn market opportunity

Shifting focus to rare and orphan diseases could be beneficial to patient outcomes and company incomes, respectively
Research & Development

Positive outputs from lab-based analysis of RSV drug candidates identified using AI

RSV drug candidates with the highest probability of success prioritised
Manufacturing

Poolbeg Pharma PLC announces directorate change
Subscribe now